Table 1.
Demographics, clinical characteristics and laboratory data of the study group.
| Patients (n = 172) | |
| Age, median (IQR) | 33 (27.3–42) |
| Gender, n (%) | |
| Males | 64 (37.2%) |
| Females | 108 (68.2%) |
| BMI, median (IQR) | 27.7 (25.4–31.6) |
| Smokers, n (%) | 15 (8.7%) |
| Medical comorbidities*, n (%) | 34 (19.8%) |
| Preexisting primary headache disorder, n (%) | |
| Migraine | 45 (26.2) |
| Tension-type headache | 46 (26.7) |
| None | 81 (47.1%) |
| Laboratory data, median (IQR) | |
| Lymphocyte count | 1400 (800–2447.5) |
| CRP (mg/L) | 12 (4.39–48) |
| D-dimer (µg/mL) | 0.36 (0.2–0.56) |
| Ferritin (ng/mL) | 130 (52.1–261.5) |
| Grading severity of COVID-19 infection, n (%) | |
| Mild | 116 (67.4%) |
| Moderate | 42 (24.4%) |
| Severe | 14 (8.1%) |
*Eighteen patients with controlled HTN (BP ≥ 140/90 or on antihypertensive medications), seven patients were diabetic, five patients had hypothyroidism, three patients had ischemic heart disease and one patient had epilepsy.
BMI: body mass index; CRP: C-reactive protein; IQR: interquartile range.